Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review

Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH7257FSA
  • |
  • Pages: 51
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pharming Group NV (PHARM)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pharming Group NV (Pharming) is a specialty pharmaceutical company which develops nutritional products for the treatment of genetic diseases and unmet medical needs. The company's flagship product, Ruconest (Rhucin in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema (HAE). Its product pipeline consists of recombinant human C1 inhibitor (rhC1INH) for the treatment of delayed graft function; and recombinant human factor VIII (rhFactor VIII) for the treatment of haemophilia A. The company has manufacturing facilities in the Netherlands and the US. It markets and sells its products through distributors and partners. Pharming is headquartered in Leiden, the Netherlands.

Pharming Group NV Key Recent Developments

Jul 26,2018: Pharming reports on financial results for the first half of 2018

May 17,2018: Pharming Group Interim Report on Financial Results for the First Quarter 2018

Mar 07,2018: Pharming Group Report on Preliminary Financial Results for 2017

Oct 26,2017: Pharming Group reports financial results for the first nine months of 2017

Jul 27,2017: Pharming Reports on Financial Results for the First Half of 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Pharming Group NV-Key Facts 5

Pharming Group NV-Key Employees 6

Pharming Group NV-Key Employee Biographies 7

Pharming Group NV-Major Products and Services 8

Pharming Group NV-History 9

Pharming Group NV-Locations And Subsidiaries 12

Head Office 12

Other Locations & Subsidiaries 12

Section 2-Company Analysis 13

Company Overview 13

Pharming Group NV-Business Description 14

Pharming Group NV-Corporate Strategy 15

Pharming Group NV-SWOT Analysis 16

SWOT Analysis-Overview 16

Pharming Group NV-Strengths 16

Pharming Group NV-Weaknesses 17

Pharming Group NV-Opportunities 18

Pharming Group NV-Threats 19

Pharming Group NV-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's Lifesciences Financial Deals and Alliances 28

Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Pharming Group NV, Recent Deals Summary 30

Section 5-Company's Recent Developments 31

Jul 26, 2018: Pharming reports on financial results for the first half of 2018 31

May 17, 2018: Pharming Group Interim Report on Financial Results for the First Quarter 2018 33

Mar 07, 2018: Pharming Group Report on Preliminary Financial Results for 2017 35

Oct 26, 2017: Pharming Group reports financial results for the first nine months of 2017 37

Jul 27, 2017: Pharming Reports on Financial Results for the First Half of 2017 38

May 17, 2017: Pharming Group Interim Report on Financial Results for the First Quarter 2017 43

Mar 09, 2017: Pharming Group: Report on Preliminary Financial Results for 2016 45

Section 6-Appendix 47

Methodology 47

Ratio Definitions 47

About GlobalData 51

Contact Us 51

Disclaimer 51

List of Figures

Pharming Group NV, Performance Chart (2013-2017) 25

Pharming Group NV, Ratio Charts 27

Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Pharming Group NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

List of Tables

Pharming Group NV, Key Facts 5

Pharming Group NV, Key Employees 6

Pharming Group NV, Key Employee Biographies 7

Pharming Group NV, Major Products and Services 8

Pharming Group NV, History 9

Pharming Group NV, Subsidiaries 12

Pharming Group NV, Key Competitors 20

Pharming Group NV, Ratios based on current share price 21

Pharming Group NV, Annual Ratios 22

Pharming Group NV, Annual Ratios (Cont...1) 23

Pharming Group NV, Annual Ratios (Cont...2) 24

Pharming Group NV, Interim Ratios 26

Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Pharming Group NV, Recent Deals Summary 30

Currency Codes 47

Capital Market Ratios 47

Equity Ratios 48

Profitability Ratios 48

Cost Ratios 49

Liquidity Ratios 49

Leverage Ratios 50

Efficiency Ratios 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

XOMA Corp

rEVO Biologics Inc

Lead Pharma Holding BV

Galapagos NV

Dyax Corp

CSL Behring LLC

Crucell NV

arGEN-X BV

Pharming Group NV, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8985
Site License
USD 250 INR 17970
Corporate User License
USD 375 INR 26955

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com